scholarly journals Immunological effectiveness of hepatitis B vaccination in deviation from vaccination schedule in healthy children and children with chronic diseases

2021 ◽  
Vol 24 (3) ◽  
pp. 163-167
Author(s):  
Dmitriy S. Yasakov ◽  
Natalya E. Tkachenko ◽  
Andrey P. Fisenko ◽  
Svetlana G. Makarova ◽  
Marina G. Vershinina ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Chronic Diseases ◽  
Vaccination Schedule ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Vaccination ◽  
Healthy Children ◽  
Immunization Schedule ◽  
The Third ◽  
Group 2 ◽  
Group 1

Introduction. Vaccination is the primary method of preventing hepatitis B (HBV). Immunization performed according to the standard schedule often provides protective level of antibodies against HBV. However, the frequency deviation of the immunization schedule in children due to unjustified medical contraindication is the current problem in Russia. At the same time, there is currently no clear strategy for patients with significant deviations of the vaccination schedule, especially regarding extending the interval between the first and third administration of the HBV vaccine. The aim is to evaluate the immunological effects of vaccination against hepatitis B in the vaccination schedule deviation in healthy children and children with chronic diseases. Materials and methods. Eighty-one 0.7-11.7 year child with a disrupted schedule of vaccination against HBV was observed. The children were divided into two groups: children vaccinated within 12-35 months (group 1, n = 48) and children immunized more than 36 months after the first vaccination (group 2, n = 33). Children with chronic forms of pathology were included in both study groups. Blood tests for HBV antibodies after vaccination were performed 1-3 months after the third vaccination. Results. The average concentration of antibodies in the range of 10-1000 mMEd/ml in children of group 1 was significantly higher than in children of group 2 (p = 0.037). In addition, children with chronic diseases were significantly more likely to have an anti-HBs titer higher than 1000 mMEd/ml after the third vaccination than healthy children (p = 0.012). Conclusion. An increase in the interval between the first and third administration of the hepatitis B vaccine leads to a rise in the number of children who are not immune to hepatitis B. Chronic diseases fail to affect the immune response due to the introduction of the hepatitis B vaccine, even if the immunization schedule is disrupted.

Response to Challenge Dose Among Young Adults Vaccinated for Hepatitis B as Infants: Importance of Detectable Residual Antibody to Hepatitis B Surface Antigen

2015 ◽  
Vol 36 (5) ◽  
pp. 529-533 ◽  
Author(s):  
Philip R. Spradling ◽  
Saleem Kamili ◽  
Jian Xing ◽  
Jan Drobeniuc ◽  
Dale J. Hu ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Hepatitis B Vaccine ◽  
Immune Memory ◽  
Hepatitis B Vaccination ◽  
Challenge Dose ◽  
Group 3 ◽  
Group 2 ◽  
Group 1

OBJECTIVETo determine whether a difference in antibody to hepatitis B surface antigen (anti-HBs) response to a hepatitis B vaccine challenge dose existed among persons with a baseline anti-HBs level of 0 mIU/mL (group 1) and those with “non-zero” levels of 0.1–4.9 (group 2) and 5.0–9.9 (group 3) mIU/mL, according to the VITROS ECi anti-HBs assay.DESIGNSubanalysis of randomized clinical trial. Response was defined as a postchallenge anti-HBs level of at least 10 mIU/mL and 4-fold rise in anti-HBs level 2 weeks after a single challenge dose of 10 vs 20 µg Engerix-B. Baseline was defined as the anti-HBs level immediately before administration of the challenge dose.SETTINGPediatric integrated healthcare system near Houston, Texas.PARTICIPANTSThree hundred nineteen US-born 16–19-year-olds who completed the hepatitis B vaccine series during the first year of life.RESULTSOne hundred seventy-eight persons had zero (group 1) and 141 (114 group 2 and 27 group 3) had non-zero anti-HBs levels at baseline. Response to the challenge dose was significantly higher among those with non-zero vs zero anti-HBs levels, irrespective of challenge dosage; only 1 person with a non-zero anti-HBs level failed to respond to the challenge dose (group 3, 27/27 [100%] vs group 2, 113/114 [99%] vs group 1, 145/178 [82%]; P<.0001).CONCLUSIONSAmong participants with residual anti-HBs levels less than 10 mIU/mL 16–19 years after primary hepatitis B vaccination during infancy, non-zero anti-HBs levels, with rare exception, indicated persistence of immune memory to HBsAg.TRIAL REGISTRATIONClinicalTrials.gov Identifier: NCT01341275Infect Control Hosp Epidemiol 2015;00(0):1–5

scholarly journals Immunization aganist hepatitis B in children from endemic zone: evaluation of the antibody response against the DNA recombinant vaccine (Engerix B-20 mcg)

1993 ◽  
Vol 35 (1) ◽  
pp. 89-92 ◽  
Author(s):  
C.R.B. Ferreira ◽  
C.F.T. Yoshida ◽  
L.A.C. Mercadante ◽  
D.F. Gomes ◽  
J.M. Oliveira ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Antibody Response ◽  
Recombinant Dna ◽  
Hepatitis B Surface Antigen ◽  
Vaccine Dose ◽  
Vaccination Schedule ◽  
Hepatitis B Vaccine ◽  
Recombinant Hepatitis ◽  
The Third ◽  
Rural Zone

A previous seroepidemiological study in the rural zone of Vargem Alta (ES) SouthEast of Brazil, showed a prevalence of up to 9% of hepatitis B surface antigen (HBsAg) in some areas. One hundred susceptible children aging 1 to 5 years old were selected and immunized with a recombinant DNA hepatitis B vaccine (Smith-Kline 20 mcg) using the 0-1-6 months vaccination schedule. Blood samples were collected at the time of the first vaccine dose (month 0) in order to confirm susceptible individuals and 1,3,6 and 8 months after the first dose , to evaluate the antibody response. Our results showed that two and five months after the second dose, 79% and 88% of children seroconverted respectively, reaching 97% after the third dose. The levels of anti-HBs were calculated in milli International Units/ml (mIU/ml) and demonstrated the markedly increase of protective levels of antibodies after the third dose. These data showed a good immunogenicity of the DNA recombinant hepatitis B vaccine when administered in children of endemic areas.

scholarly journals Effect of educational intervention on knowledge, attitude and practice of hepatitis B vaccine among medical students

2018 ◽  
Vol 7 (5) ◽  
pp. 992 ◽  
Author(s):  
Sareetha A. V. ◽  
Nagabushan H. ◽  
Supriya K. H.
Keyword(s):  
Medical Students ◽  
Hepatitis B ◽  
Educational Intervention ◽  
Vaccination Schedule ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Vaccination ◽  
Attitude And Practice ◽  
Post Test ◽  
The Impact ◽  
Knowledge Attitude And Practice

Background: Aim of the study were to assess the impact of education on knowledge, attitude and practice of Hepatitis B vaccine among medical students and to educate the students regarding Hepatitis B vaccination.Methods: Non-randomized before and after comparison study was conducted to evaluate changes in knowledge, attitude and practice of Hepatitis B vaccination (HBV), assigning structured questionnaire of 26 different statements concerning knowledge, attitude and practice by pre and post educational intervention on Hepatitis B and its vaccination.Results: The study was conducted among 100 second year medical students. The response rate was 100%. There was statistically significant improvement in knowledge from pre-test mean scores for modes of transmission (87.4+4.70 vs 95.8+1.61; p=0.0001), preventive measures (92+0.47 vs 98+0.94; p=0.001) and Hepatitis B vaccine (71+4.72 to 84.7+6.65; p=0.0001) to post-test. While the increase in mean scores from pre-test for attitude (68.6+9.21 vs 77.43+11.1) and practice (55+25.41 vs 65.6+32.6) were statistically significant in post-test (p=0.0001; p=0.001 respectively).Conclusions: Structured educational intervention among medical students about Hepatitis B vaccination showed improved knowledge and behaviour and also increased the percentage of students willing to get screened and their participation in health education programmes related to Hepatitis B. However, there is slight lack of knowledge regarding the transmission of Hepatitis B and its vaccination schedule. In this regard, implementation and evaluation of educational intervention is needed as a preventative measure.

scholarly journals Factors associated with Hepatitis B screening and completion of vaccination schedule among young psychoactive substance users in Kampala's informal settlements, Uganda

2020 ◽  
Author(s):  
Tonny Ssekamatte ◽  
John Bosco Isunju ◽  
Joan Nankya Mutyoba ◽  
Moses Tetui ◽  
Richard K. Mugambe ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Informal Settlements ◽  
Vaccination Schedule ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Vaccination ◽  
Hepatitis B Infection ◽  
Psychoactive Substance ◽  
Substance Users ◽  
Factors Associated ◽  
Hepatitis B Screening

Abstract Background Young psychoactive substance users exhibit high-risk behaviours which can increase their risk to Hepatitis B infection. However, there is limited information on screening, and completion of the Hepatitis B vaccination schedule among young psychoactive substance users in informal settlements. Therefore, this study determined the factors associated with Hepatitis B screening, and completion of the Hepatitis B vaccination schedule among young psychoactive substance users in Kampala’s informal settlements, Uganda. Methods A cross-sectional study design was used. Respondent driven sampling was used to enroll 768 respondents from 12 informal settlements. Data were collected using a structured questionnaire and analysed using Stata version 14. A “modified” Poisson regression analysis was done to determine the factors associated with Hepatitis B screening while logistic regression was used to determine the factors associated with completion of the Hepatitis B vaccination schedule. Results Out of the 768 respondents, only 13.3% had ever screened for Hepatitis B and 2.7% had completed the Hepatitis B vaccine schedule. Being a female (aPR 1.61, 95% CI: 1.11-2.33), earning a monthly income >USD 136 (aPR 1.78, 95% CI: 1.11-2.86); completion of the Hepatitis B vaccination schedule (aPR 1.85, 95% CI: 1.26-2.70); lack of awareness about the recommended Hepatitis B vaccine dose (aPR 0.43, 95% CI: 0.27-0.68); and the belief that the Hepatitis B vaccine is effective in preventing Hepatitis B infection (aPR 3.67, 95% CI: 2.34-5.73) were associated with “ever screening” for Hepatitis B. Knowledge about the recommended Hepatitis B vaccine dose (aOR 0.06, 95% CI: 0.01-0.35); “ever screening” for hepatitis B (aOR 9.68, 95% CI: 2.17-43.16) and the belief that the hepatitis B vaccine is effective in preventing Hepatitis B infection (aOR 11.8, 95% CI: 1.13-110.14) were associated with completion of the Hepatitis B vaccination schedule. Conclusion Our findings indicate a low prevalence of Hepatitis B screening and completion of the Hepatitis B vaccination schedule among young psychoactive substance users in informal urban settings. It is evident that lack of awareness about Hepatitis B is associated with the low screening and vaccination rates. We recommend mass sensitisation of young psychoactive substance users in urban informal settlements on Hepatitis B.

scholarly journals Circulating Tfh cell and subsets distribution are associated with low‐responsiveness to hepatitis B vaccination

2021 ◽  
Vol 27 (1) ◽  
Author(s):  
Mingjuan Yin ◽  
Yongzhen Xiong ◽  
Dongmei Liang ◽  
Hao Tang ◽  
Qian Hong ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Vaccination ◽  
Cellular Mechanisms ◽  
Immunological Responses ◽  
Follicular Helper ◽  
Low Responders ◽  
Specific Subset ◽  
Antibody Titers

Abstract Background An estimated 5–10 % of healthy vaccinees lack adequate antibody response following receipt of a standard three-dose hepatitis B vaccination regimen. The cellular mechanisms responsible for poor immunological responses to hepatitis B vaccine have not been fully elucidated to date. Methods There were 61 low responders and 56 hyper responders involved in our study. Peripheral blood samples were mainly collected at D7, D14 and D28 after revaccinated with a further dose of 20 µg of recombinant hepatitis B vaccine. Results We found low responders to the hepatitis B vaccine presented lower frequencies of circulating follicular helper T (cTfh) cells, plasmablasts and a profound skewing away from cTfh2 and cTfh17 cells both toward cTfh1 cells. Importantly, the skewing of Tfh cell subsets correlated with IL-21 and protective antibody titers. Based on the key role of microRNAs involved in Tfh cell differentiation, we revealed miR-19b-1 and miR-92a-1 correlated with the cTfh cell subsets distribution and antibody production. Conclusions Our findings highlighted a decrease in cTfh cells and specific subset skewing contribute to reduced antibody responses in low responders.

scholarly journals SAT0140 SAFETY OF TOFACITINIB THERAPY IN HBSAG CARRIERS WITH RHEUMATOID ARTHRITIS: A PROSPECTIVE STUDY

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1008.2-1008
Author(s):  
L. Fang ◽  
Z. Lin ◽  
Z. Liao ◽  
O. Jin ◽  
Y. Pan ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Viral Load ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Hbv Infection ◽  
Hbsag Carriers ◽  
B Virus ◽  
Group 2 ◽  
A Prospective Study ◽  
Group 1

Background:Targeted synthetic DMARDs (ts-DMARDs) are becoming more available and affordable in developing countries, where the prevalence of hepatitis B virus (HBV) infection is still an important public health issue. The safety of ts-DMARDs therapy in terms of the reactivation of hepatitis B virus (HBV) infection need more concern. Rare data from a prospective study focus on the use of ts-DMARDs in patients with concurrent rheumatoid arthritis (RA) and HBV infection were available by now.Objectives:To evaluate the influence of tofacitinib on reactivation of HBV infection in HBsAg carriers with RA.Methods:In this 52 weeks observation, HBsAg carriers with active RA (DAS28>5.1) despite failed combined treatment with MTX and other non-biological DMARDs were enrolled. Patients must have normal liver function prior to study. All patients received therapy with tofacitinib (5mg twice daily) and concomitant MTX (10-12.5mg/w). Entecavir was prescribed preventively for patients who had a baseline HBV load >2000 copy/ml (group 1), and Lamivudin for patients with HBV load ≤ 2000 copy/ml (group 2). Liver enzymes (AST/ALT) and HBV viral load were monitored every 4 weeks. Increased viral load and abnormal liver function were managed according to expert opinion.Results:Thirteen patients (10 female) were recruited. Nine patients had a baseline viral load >2000 copy/ml (group 1, with preventive Entecavir), and the other 4 patients had a viral load ≤ 2000 copy/ml (group 2, with preventive Lamivudin). Two patients from group 1 discontinued tofacitinib at week 12 due to ineffectiveness, and both continued taking Entecavir for another 3 months after the discontinuation of tofacitinib.No reactivation of hepatitis B was observed in patients from group 1. One patients (female, 54 years old) from group 2 underwent a mild increase of both ALT and AST (67 and 56 IU/L, respectively) at week 16. An elevated viral load (4.9e6 copies/ml, baseline 1.4e3) and a HBV YMDD mutant was also found. The tofacitinib treatment continued. After prescription of Adefovir (combined with the pre-existing Lamivudin), both liver enzyme and viral load decreased to normal range in 8 weeks and remained normal throughout the study.Conclusion:An aggressive Tofacitinib + MTX therapy may be a safe option for HBsAg carriers with cs-DMARDs refractory RA. More active and effective prophylaxis strategy may be recommended to reduce the risk of HBV reactivation during the treatment.References:[1]Chen YM, Huang WN, Wu YD, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study. Ann Rheum Dis 2018; 77:780-2.Disclosure of Interests: :None declared

scholarly journals Latent Profiles of Burnout, Self-Esteem and Depressive Symptomatology among Teachers

2020 ◽  
Vol 17 (18) ◽  
pp. 6760
Author(s):  
Inmaculada Méndez ◽  
Juan Pedro Martínez-Ramón ◽  
Cecilia Ruiz-Esteban ◽  
José Manuel García-Fernández
Keyword(s):  
Emotional Exhaustion ◽  
Depressive Symptomatology ◽  
Maslach Burnout Inventory ◽  
Self Esteem ◽  
Personal Accomplishment ◽  
The Self ◽  
Teaching Staff ◽  
The Third ◽  
Group 2 ◽  
Group 1

Burnout is a reality in the teaching profession. Specifically, teaching staff usually have higher burnout rates. The present study aims to analyze the different burnout profiles and to verify if there were differences between burnout profiles in depressive symptomatology and in the self-esteem of the teachers at school. The total number of participants was 210 teachers from 30 to 65 years. The first scale was the Maslach burnout inventory, the second scale was the Self-Rating depression scale and the third scale was the Rosenberg Self-Esteem Scale. The latent class analysis identified three burnout profiles: the first group with a high level of emotional exhaustion, low personal accomplishment and depersonalization (high burnout); the second group with low emotional exhaustion, low depersonalization and high personal accomplishment (low burnout) and the third group with low depersonalization, low emotional exhaustion and low personal accomplishment (moderate burnout). The results revealed that there were differences in depressive symptomatology (group 1 obtained higher scores than group 2 and group 3) and self-esteem (group 2 obtained higher scores than group 1). The psychological balance and health of teachers depend on preventing the factors that have been associated with this syndrome.

Recommended Childhood Immunization Schedule

PEDIATRICS ◽  
1996 ◽  
Vol 97 (1) ◽  
pp. 143-143
Author(s):  
Keyword(s):  
Hepatitis B ◽  
American Academy ◽  
Health Care Providers ◽  
Hepatitis B Vaccine ◽  
News Article ◽  
Immunization Schedule ◽  
Care Providers ◽  
Childhood Immunization ◽  
Varicella Zoster ◽  
Control And Prevention

The Recommended Childhood Immunization Schedule for 1995 was developed by the Committee on Infectious Diseases (COID) of the American Academy of Pediatrics in collaboration with the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) and the American Academy of Family Physicians (AAFP).1 Since the January 1995 publication, the AAP, ACIP, and AAFP have agreed on the following revisions: 1. The revised schedule is dated January-June 1996 and will be reprinted in July 1996 with any indicated changes. Incorporating dates in the chart will assure health care providers that they are using the most current schedule. 2. A column has been added to indicate that the second dose of hepatitis B vaccine can be administered at 1 month of age, provided that at least 1 month has elapsed since the first dose was given. Also, the doses of vaccine are provided in micrograms by individual product instead of volume, as several different concentrations of recombivax-HB (Merck, Sharp and Dohme) vaccine are available. 3. A bar has been added at 11-12 years of age to indicate that adolescents who have not previously received three doses of hepatitis B vaccine should initiate or complete the three-dose series. 4. Varicella zoster virus vaccine (Var) has been added to the schedule. In addition to the previously issued Academy recommendations, answers to commonly asked questions are addressed in a recent AAP News article.2,3 5. Information on inactivated poliomyelitis vaccine (IPV) has been added to reflect the Academy's current policy.

Extending the multistage surgical strategy for recurrent initially low-grade gliomas: functional and oncological outcomes in 31 consecutive patients who underwent a third resection under awake mapping

2021 ◽  
pp. 1-10 ◽  
Author(s):  
Noor Hamdan ◽  
Hugues Duffau
Keyword(s):  
High Rate ◽  
Karnofsky Performance Scale ◽  
Consecutive Series ◽  
Low Grade ◽  
Oncological Treatment ◽  
The Third ◽  
Oncological Outcomes ◽  
Group 2 ◽  
Group 1

OBJECTIVE Maximal safe resection is the first treatment in diffuse low-grade glioma (DLGG). Due to frequent tumor recurrence, a second surgery has already been reported, with favorable results. This study assesses the feasibility and functional and oncological outcomes of a third surgery in recurrent DLGG. METHODS Patients with DLGG who underwent a third functional-based resection using awake mapping were consecutively selected. They were classified into group 1 in cases of slow tumor regrowth or group 2 if a radiological enhancement occurred during follow-up. All data regarding clinicoradiological features, histomolecular results, oncological treatment, and survival were collected. RESULTS Thirty-one patients were included, with a median age of 32 years. There were 20 astrocytomas and 11 oligodendrogliomas in these patients. Twenty-one patients had medical oncological treatment before the third surgery, consisting of chemotherapy in 19 cases and radiotherapy in 8 cases. No neurological deficit persisted after the third resection except mild missing words in 1 patient, with 84.6% of the patients returning to work. The median follow-up duration was 13.1 ± 3.4 years since diagnosis, and 3.1 ± 2.9 years since the third surgery. The survival rates at 7 and 10 years were 100% and 89.7%, respectively, with an estimated median overall survival of 17.8 years since diagnosis. A comparison between the groups showed that the Karnofsky Performance Scale score dropped below 80 earlier in group 2 (14.3 vs 17.1 years, p = 0.01). Median residual tumor volume at the third surgery was smaller (2.8 vs 14.4 cm3, p = 0.003) with a greater extent of resection (89% vs 70%, p = 0.003) in group 1. CONCLUSIONS This is the first consecutive series showing evidence that, in select patients with progressive DLGG, a third functional-based surgery can be achieved using awake mapping with low neurological risk and a high rate of total resection, especially when reoperation is performed before malignant transformation.

Risk of Exposure, Perception and Vaccination Status of Chronic Viral Hepatitis among Health Care Workers in Benue State, North Central Nigeria

2021 ◽  
Vol 2 (1) ◽  
pp. 57-62
Author(s):  
A S Obekpa ◽  
A O Malu ◽  
R Bello ◽  
M Duguru
Keyword(s):  
Health Care ◽  
Hepatitis B ◽  
Viral Hepatitis ◽  
Health Care Workers ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Vaccination ◽  
Care Workers ◽  
Risk Of Exposure ◽  
Needle Prick ◽  
Needle Prick Injury

Health care workers are high-risk group for contracting hepatitis B and C virus infections. Hepatitis B and C can be contracted in the hospital setting by needle prick injury, contact with blood (and body fluids) and during invasive medical procedures. This study aims to assess the risk of exposure, the concern or perception of healthcare workers about getting infected (with HBV and/or HCV) from the workplace and the level of HBV vaccination uptake among them. The study was carried out during a capacity building workshop organized for health care workers from all the Local Government Areas in Benue State. A self-administered questionnaire was distributed to 168 participants in attendance, after obtaining verbal consent. One hundred and thirty-eight (138) questionnaires were properly filled and returned, 115 (83.3%) have had needle prick injury, 127 (92%) have had blood spilling on them and 118 (85.5%) have been involved in the management of hepatitis patients. One hundred and nineteen (86.2%) were afraid of contracting hepatitis infection from their place of work, 133 (96.4%) were aware of hepatitis B vaccine for adult, 87 (63%) had received at least one dose of hepatitis B vaccine but only 56 (40.6%) received the complete three doses. Health care workers in Benue State are aware of the risk of contracting viral hepatitis at their workplace and are concerned about this risk. However, the uptake of hepatitis B vaccination among them remains poor.

Sign in / Sign up

Export Citation Format

Share Document